Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome

World Journal of Gastroenterology

Volumn 20, Issue 39, 2014, Pages 14142-14155

  Ghaziani, Tahereh ^a   Sendi, Hossein ^b   Shahraz, Saeid ^c   Zamor, Philippe ^b   Bonkovsky, Herbert L ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

^c BRANDEIS UNIVERSITY   (United States)

Author keywords

Cirrhosis; End stage liver disease; Entecavir; Genetic variants; Hepatitis b; Hepatocellular carcinoma; Interferon alpha; Lamivudine; Liver transplantation; Tenofovir

Indexed keywords

ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN;

COST EFFECTIVENESS ANALYSIS; DELTA AGENT HEPATITIS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MEDLINE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; ADVERSE EFFECTS; COMPLICATION; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COST; DRUG EFFECTS; ECONOMICS; END STAGE LIVER DISEASE; GENETICS; GENOTYPE; IMMUNOLOGY; MUTATION; PATHOGENICITY; PATIENT SELECTION; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; END STAGE LIVER DISEASE; GENOTYPE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MUTATION; PATIENT SELECTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84910125730     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i39.14142     Document Type: Review

References (85)

1. Chan HL, Wong VW. Boyer TD, Manns MP, Sanyal AJ, editors. Zakim Boyer's Hepatology-A Textbook of Liver Disease. 6th ed. Phila, PA: Elsevier-Saunders, 2012: 540-563
2. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847 [PMID: 8247035 DOI: 10.1056/NEJM199312163292503]
3. Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47: 289-309 [PMID: 15564741 DOI: 10.1159/000080872]
4. Hadziyannis SJ. Viral hepatitis: an overview. Br J Clin Pract 1995; 49: 267-268 [PMID: 7492465]
5. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-591 [PMID: 2570285]
6. Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol 1999; 73: 1239-1244 [PMID: 9882327]
7. Sendi H, Mehrab-Mohseni M, Zali MR, Norder H, Magnius LO. T1764G1766 core promoter double mutants are restricted to Hepatitis B virus strains with an A1757 and are common in genotype D. J Gen Virol 2005; 86: 2451-2458 [PMID: 16099903 DOI: 10.1099/vir.0.81023-0]
8. Asim M, Malik A, Sarma MP, Polipalli SK, Begum N, Ahmad I, Khan LA, Husain SA, Akhtar N, Husain S, Thayumanavan L, Singla R, Kar P. Hepatitis B virus BCP, Precore/core, X gene mutations/genotypes and the risk of hepatocellular carcinoma in India. J Med Virol 2010; 82: 1115-1125 [PMID: 20513073 DOI: 10.1002/jmv.21774]
9. Elkady A, Tanaka Y, Kurbanov F, Oynsuren T, Mizokami M. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. J Gastroenterol Hepatol 2008; 23: 474-481 [PMID: 18318825 DOI: 10.1111/j.1440-1746.2008.05321.x]
10. Khan A, Al Balwi MA, Tanaka Y, Hajeer A, Sanai FM, Al Abdulkarim I, Al Ayyar L, Badri M, Saudi D, Tamimi W, Mizokami M, Al Knawy B. Novel point mutations and mutational complexes in the enhancer II, core promoter and precore regions of hepatitis B virus genotype D1 associated with hepatocellular carcinoma in Saudi Arabia. Int J Cancer 2013; 133: 2864-2871 [PMID: 23740667 DOI: 10.1002/ijc.28307]
11. Sunbul M, Sugiyama M, Kurbanov F, Leblebicioglu H, Khan A, Elkady A, Tanaka Y, Mizokami M. Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. Microbiol Immunol 2013; 57: 122-129 [PMID: 23252849 DOI: 10.1111/1348-0421.12011]
12. Angus PW, Locarnini SA, McCaughan GW, Jones RM, McMillan JS, Bowden DS. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995; 21: 14-18 [PMID: 7806147]
13. Wu TJ, Chan KM, Chou HS, Lee CF, Wu TH, Chen TC, Yeh CT, Lee WC. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol 2013; 20: 3582-3590 [PMID: 23760589 DOI: 10.1245/s10434-013-3023-5]
14. Kim KH, Lee KH, Chang HY, Ahn SH, Tong S, Yoon YJ, Seong BL, Kim SI, Han KH. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 2003; 71: 367-375 [PMID: 12966541 DOI: 10.1002/jmv.10503]
15. McMillan JS, Bowden DS, Angus PW, McCaughan GW, Locarnini SA. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 1996; 24: 1371-1378 [PMID: 8938164 DOI: 10.1002/hep.510240610]
16. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: related risk factors and perspective. Hepatobiliary Pancreat Dis Int 2005; 4: 502-508 [PMID: 16286252]
17. Berenguer M, Wright TL. Treatment of recurrence of hepatitis B in transplant patients. J Hepatol 2003; 39 Suppl 1: S190-S193 [PMID: 14708702]
18. Riediger C, Berberat PO, Sauer P, Gotthardt D, Weiss KH, Mehrabi A, Merle U, Stremmel W, Encke J. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant 2007; 22 Suppl 8: viii37-viii46 [PMID: 17890261 DOI: 10.1093/ndt/gfm655]
19. Ben-Ari Z, Ashur Y, Daudi N, Shmilovitz-Wiess H, Brown M, Sulkes J, Klein A, Mor E, Tur-Kaspa R, Shouval D. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. Clin Transplant 2004; 18: 415-422 [PMID: 15233819 DOI: 10.1111/j.1399-0012.2004.00182.x]
20. Girlanda R, Mohsen AH, Smith H, Sablon E, Yuen MF, O'Grady J, Muiesan P, Rela M, Heaton N, Norris S. Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease. Liver Transpl 2004; 10: 58-64 [PMID: 14755779 DOI: 10.1002/lt.20004]
21. Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl 2008; 14 Suppl 2: S8-S14 [PMID: 18825720 DOI: 10.1002/lt.21616]
22. Lapiński TW, Pogorzelska J, Flisiak R. HBV mutations and their clinical significance. Adv Med Sci 2012; 57: 18-22 [PMID: 22430043 DOI: 10.2478/v10039-012-0006-x]
23. Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 2013; 33 Suppl 1: 116-124 [PMID: 23286855 DOI: 10.1111/liv.12069]
24. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol 2013; 108: 942-948 [PMID: 23629601 DOI: 10.1038/ajg.2013.111]
25. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001; 8: 237-247 [PMID: 11385295 DOI: 10.1007/BF02256597]
26. Schätzl HM, Sieger E, Jilg W, Nitschko H, Zachoval R. Variability of the Hepatitis B Surface Protein in HBV-Infected Liver Transplant Recipients. J Biomed Sci 1997; 4: 146-154 [PMID: 11725147]
27. Shen ZY, Zheng WP, Deng YL, Song HL. Variations in the S and P regions of the hepatitis B virus genome under immunosuppression in vitro and in vivo. Viral Immunol 2012; 25: 368-378 [PMID: 22946668]
28. Ueda Y, Marusawa H, Egawa H, Okamoto S, Ogura Y, Oike F, Nishijima N, Takada Y, Uemoto S, Chiba T. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther 2011; 16: 479-487 [PMID: 21685535 DOI: 10.3851/IMP1771]
29. Luo Y, Lo CM, Cheung CK, Lau GK, Fan ST, Wong J. Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl 2007; 13: 71-79 [PMID: 17031830 DOI: 10.1002/lt.20887]
30. Sendi H, Mehrab-Mohseni M, Shahraz S, Norder H, Alavian SM, Noorinayer B, Zali MR, Pumpens P, Bonkovsky HL, Magnius LO. CTL escape mutations of core protein are more frequent in strains of HBeAg negative patients with low levels of HBV DNA. J Clin Virol 2009; 46: 259-264 [PMID: 19748824 DOI: 10.1016/j.jcv.2009.08.002]
31. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185 [PMID: 4933363]
32. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnićk GL, Elveback IR, Schoenfield LJ. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833 [PMID: 4538724]
33. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195 [PMID: 11093723 DOI: 10.1053/jhep.2000.19789]
34. Webster G, Barnes E, Burroughs A, Dusheiko G. Organ transplantation and discrimination. Patients with hepatitis B should not be given low priority. BMJ 2000; 320: 1600-1601 [PMID: 10896428]
35. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116-1121 [PMID: 8462800]
36. Wright HI, Gavaler JS, Van Theil DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53: 121-124 [PMID: 1733058]
37. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215 [PMID: 8898039]
38. Fontana RJ, Keeffe EB, Han S, Wright T, Davis GL, Lilly L, Carey W, Fried M, Jensen D, Luketic V, Kowdley KV, Lok AS. Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients. Hepatology 1999; 30: 301a
39. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003; 3: 250-258 [PMID: 12614278]
40. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90 [PMID: 14699490]
41. Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101 [PMID: 14699491]
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807 [PMID: 12606734 DOI: 10.1056/NEJMoa021812]
43. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816 [PMID: 12606735 DOI: 10.1056/NEJMoa020681]
44. Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-734 [PMID: 19517525 DOI: 10.1002/hep.23044]
45. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010 [PMID: 16525137 DOI: 10.1056/NEJMoa051285]
46. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514 [PMID: 19280622 DOI: 10.1002/hep.22841]
47. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 49: 72-79 [PMID: 19065670 DOI: 10.1002/hep.22658]
48. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, Enejosa J. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2007; 8: 164-172 [PMID: 17621463 DOI: 10.1310/hct0803-164]
49. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589 [PMID: 9696028 DOI: 10.1002/hep.510280241]
50. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937 [PMID: 17383422 DOI: 10.1053/j.gastro.2007.01.005]
51. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700 [PMID: 18456569 DOI: 10.1016/j.cgh.2008.02.055]
52. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-1190 [PMID: 21656655 DOI: 10.1002/lt.22354]
53. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013; 13: 353-362 [PMID: 23137006 DOI: 10.1111/j.1600-6143.2012.04315.x]
54. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, Saab S, Durazo F, Goldstein L, Farmer D, Ghobrial RM, Busuttil RW. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182-187 [PMID: 12548512 DOI: 10.1053/jlts.2003.50002]
55. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258 [PMID: 16447195 DOI: 10.1002/lt.20701]
56. Wesdorp DJ, Knoester M, Braat AE, Coenraad MJ, Vossen AC, Claas EC, van Hoek B. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol 2013; 58: 67-73 [PMID: 23880162 DOI: 10.1016/j.jcv.2013.06.035]
57. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013; 19: 594-601 [PMID: 23447407 DOI: 10.1002/lt.23628]
58. Anders M, Orozco F, Goldaracena N, Quiñonez E, McCormack L, Mastai R. [Efficacy of the association of a single dose of hepatitis B hyperimmune gammaglobulin and entecavir in the prophylaxis of hepatitis B after liver transplantation: experience of a single center in Argentina]. Acta Gastroenterol Latinoam 2013; 43: 121-125 [PMID: 23940912]
59. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013; 19: 268-274 [PMID: 23447403 DOI: 10.1002/lt.23600]
60. Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009; 15: 413-420 [PMID: 19326401 DOI: 10.1002/lt.21712]
61. Dan YY, Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006; 12: 736-746 [PMID: 16628682 DOI: 10.1002/lt.20685]
62. Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005; 11: 4344-4350 [PMID: 16038032]
63. HBIG Product Information (U.S. Market), updated June 2010. Available from: URL: http://www.cdc.gov/hepatitis/PDFs/HBIG-Products&Distributors.pdf
64. Sutter Health. Financial Matters: Liver Transplant Costs. Available from: URL: http://www.cpmc.org/advanced/liver/patients/topics/finance.html
65. Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant 2012; 26: E561-E569 [PMID: 23061767 DOI: 10.1111/ctr.12022]
66. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203-1208 [PMID: 15114086]
67. Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T. Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective. Clinicoecon Outcomes Res 2012; 4: 227-235 [PMID: 22977309 DOI: 10.2147/CEOR.S31784]
68. Ahn JD, Cohen S. Oral antiviral therapy without long term maintenance hepatitis B immunoglobulin to prevent hepatitis B recurrence in liver transplant patients [abstract]. J Hepatol 2008; 48 suppl 2: S73-S74
69. PDR Staff. Red Book. 113th ed. Montvale, NJ: Thomson Healthcare, 2009
70. Smith VE, Bruno CJ. The search for cost-effective treatment of chronic hepatitis B. J Manag Care Pharm 2008; 14: 61-64 [PMID: 18240883]
71. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS, Emre S, Soldevila-Pico C, Reddy KR, Ishitani MB, Tran TT, Pruett TL, Lok AS. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823-1833 [PMID: 20346062 DOI: 10.1111/j.1600-6143.2010.03046.x]
72. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, Alessandria C, Franchello A, Salizzoni M, Rizzetto M. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409 [PMID: 15776431 DOI: 10.1002/lt.20402]
73. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012; 143: 619-628.e1 [PMID: 22643350 DOI: 10.1053/j.gastro.2012.05.037]
74. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72 [PMID: 21254162 DOI: 10.1002/hep.23952]
75. Samuel D, Feray C, Bismuth H. Hepatitis viruses and liver transplantation. J Gastroenterol Hepatol 1997; 12: S335-S341 [PMID: 9407355]
76. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890-1899; quiz 2155 [PMID: 18424269 DOI: 10.1053/j.gastro.2008.02.064]
77. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm G. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl 2013; 19: 1020-1029 [PMID: 23852663 DOI: 10.1002/lt.23703]
78. Hshieh TT, Sundaram V, Najarian RM, Hanto DW, Karp SJ, Curry MP. Hepatitis B surface antigen as a marker for recurrent, metastatic hepatocellular carcinoma after liver transplantation. Liver Transpl 2012; 18: 995-998 [PMID: 22829419 DOI: 10.1002/lt.23465]
79. Perrillo R, Buti M, Durand F, Charlton M, Gadano A, Cantisani G, Loong CC, Brown K, Hu W, Lopez-Talavera JC, Llamoso C. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl 2013; 19: 887-895 [PMID: 23788462 DOI: 10.1002/lt.23690]
80. Zaidan M, Lescure FX, Brochériou I, Dettwiler S, Guiard-Schmid JB, Pacanowski J, Rondeau E, Pialoux G, Girard PM, Ronco P, Plaisier E. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin J Am Soc Nephrol 2013; 8: 930-938 [PMID: 23430209 DOI: 10.2215/CJN.10051012]
81. Saab S, Desai S, Tsaoi D, Durazo F, Han S, McClune A, Holt C, Farmer D, Goldstein L, Busuttil RW. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011; 11: 511-517 [PMID: 21299826 DOI: 10.1111/j.1600-6143.2010.03416.x]
82. Stravitz RT, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, Sanyal AJ, Cotterell AH, Posner MP, Fisher RA. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012; 32: 1138-1145 [PMID: 22348467 DOI: 10.1111/j.1478-3231.2012.02770.x]
83. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF, Gigou M, Bismuth A, Mathieu D, Gentilini P. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-339 [PMID: 7843702 DOI: 10.1002/hep.1840210211]
84. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 14-18 [PMID: 9987458]
85. Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, Guarrera JV, Emond JC, Brown RS. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation 2013; 95: 960-965 [PMID: 23545507 DOI: 10.1097/TP.0b013e3182845f97]